#bladdercancer Highlights from #ASCO24- practice-informing data (not practice-changing) IMO-1) EV-pembro PRO (maintains quality of life and meaningfully improved pain) Shilpa Gupta Tom Powles, 2) Analysis of CRs with GC-nivolumab (enriched in LN-only disease which exhibited 63% CR

#ASCO24 annual conference - pleased to share my commentary on practice-informing advances in #urothelialcarcinoma #bladdercancer- from AdventHealth Central Florida #cancer Institute opmed.doximity.com/articles/bladd… via Doximity

Circulating tumor (ct)-DNA for evaluating MRD (molecular/minimal residual disease) in #bladdercancer: In this editorial in European Urology, we discuss tumor-informed ctDNA: 1) based on whole-exome sequencing of the tumor, 2) based on whole genome sequencing (WGS) of the tumor and 3)

Developmental Therapeutics #clinicaltrial Highlights From #ASCO24 - pleased to bring these highlights from AdventHealth Central Florida AdventHealth | @vumedi #earlydrugdevelopment #Phase1 vumedi.com/video/developm…

In this episode of Oncology Unplugged, Drs 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 and Guru P. Sonpavde, MD discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer. #oncology onclive.com/view/park-and-…

Honored to lecture on #bladdercancer #kidneycancer at 'Best of @asco' #ASCO24 Miami #Florida hosted by Dr. Luis E. Raez FLASCO - along with many great speakers - Manmeet Ahluwalia, MD, MBA, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Kashyap Patel, MD cloud-cme.com

ACEi (angiotensin converting enzyme inhibitor) intake was associated with increased pathologic complete remission (pCR) in patients with muscle-invasive #bladdercancer receiving neoadjuvant (pre-operative) #chemotherapy prior to radical cystectomy( especially those with higher

Pleased to review emerging #vaccine #immunotherapy approaches to treat #bladdercancer #urothelialcarcinoma - we discuss 1) peptide, 2) cellular and 3) nucleic acid (DNA, RNA) approaches - Several challenges remain: 1) heterogeneity of cancer cells, 2) Immunogenicity of

Phase I #earlydrugdevelopment update from AdventHealth Central Florida AdventHealth #cancer Institute, Orlando #Florida - We continue to grow & coauthor or lead presentations at major conferences such as #ASCO & #ESMO - we are the largest program in central Florida & eager to expand our

dMMR and MSI-H: ~3 times more prevalent in upper tract urothelial carcinoma (dMMR 8.95%; MSI-H 8.36%) than in bladder cancer (dMMR 3.09%; MSI-H 2.11%), associated with sensitivity to ICI & resistance to chemotherapy; MSI-H more common in localized vs. metastatic disease-

#ESMO24 #bladdercancer- top 3 presentations (in my opinion) ⁦PracticeUpdate⁩ practiceupdate.com/content/esmo-2…

High-risk muscle-invasive #urothelialcarcinoma #bladdercancer after radical surgery-disease-free survival was significantly longer with adjuvant pembrolizumab than with observation in the Phase III AMBASSADOR #clinicaltrial- median 29.6 vs. 14.2 months (HR 0.73; P=0.003)-honored